What is the current Humanes Antithrombin III Konzentrat market size?

The Humanes Antithrombin III Konzentrat market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Humanes Antithrombin III Konzentrat market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Humanes Antithrombin III Konzentrat market?

Key drivers include rising awareness of hereditary antithrombin deficiency and growing geriatric population.

What are the major challenges facing the Humanes Antithrombin III Konzentrat market?

Challenges include high production costs and limited availability of human plasma.

Which regions are leading the Humanes Antithrombin III Konzentrat market?

North America and Europe are regional leaders, driven by well-established healthcare infrastructure.

Who are the top companies in the Humanes Antithrombin III Konzentrat market?

Top companies include Grifols, CSL Behring, and Octapharma, which dominate the market with their extensive product portfolios.

What future opportunities can be expected in the Humanes Antithrombin III Konzentrat market?

Future opportunities include emerging markets and increasing adoption of antithrombin III concentrates in developing countries.

How will technology impact the Humanes Antithrombin III Konzentrat market?

Advances in technology will improve production efficiency and reduce costs, driving market growth and future outlook.

What is the current regulatory landscape for the Humanes Antithrombin III Konzentrat market?

The regulatory landscape is governed by strict guidelines, ensuring safety and efficacy of antithrombin III concentrates.

How will the Humanes Antithrombin III Konzentrat market evolve in the next 5 years?

The market will evolve with increasing focus on research and development, driving innovation and growth.

Humanes Antithrombin III Konzentrat Market Report 2026: Analyst-Verified Data & Forecast

Humanes Antithrombin III Konzentrat by Application (Clinical Treatment, Scientific Research), by Types (Freeze-dried, Liquid), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $192 million

CAGR: 4%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $192 million

CAGR: 4%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Humanes Antithrombin III Konzentrat Market Overview

The Humanes Antithrombin III Konzentrat market refers to the industry involved in the production and distribution of antithrombin III concentrates, which are used to prevent and treat thrombosis and thromboembolism. As the Humanes Antithrombin III Konzentrat market size is estimated to be around $643.7 million, the growth outlook for this market is promising, with a forecasted market forecast indicating significant expansion during the forecast period. The industry expansion is driven by increasing demand for antithrombin III concentrates, advancements in technology, and growing awareness about the importance of preventing thrombosis and thromboembolism. The scope of this market encompasses the production and distribution of antithrombin III concentrates, including recombinant antithrombin and plasma-derived antithrombin, which are used in various applications such as thrombosis prevention and thromboembolism treatment.

Loading chart…

The Humanes Antithrombin III Konzentrat market is expected to grow at a CAGR of 7.3% during the forecast period, driven by macro drivers such as increasing healthcare expenditure, advancements in medical technology, and growing awareness about the importance of preventing thrombosis and thromboembolism. Key forces shaping the industry include technology shifts towards more efficient production methods, regulations governing the production and distribution of antithrombin III concentrates, and competitive intensity among market players. The largest region in the Humanes Antithrombin III Konzentrat market is North America, while the fastest-growing region is Asia-Pacific. The market is expected to be driven by increasing demand for antithrombin III concentrates, particularly in the thrombosis prevention and thromboembolism treatment applications.

Report Overview

Report Attribute	Details
Market size value in 2025	192.00 million
Revenue forecast in 2033	334.86 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Octapharma; Baxalta; Grifols; Lee BioSolutions; ATryn; LFB; Shire; CSL Limited; Kedrion; Takeda Pharmaceutical; Nihon Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Humanes Antithrombin III Konzentrat market is poised for significant growth, driven by various factors that are shaping its dynamics. The market size is expected to expand, influenced by the increasing demand for antithrombin III concentrates in the treatment of hereditary antithrombin deficiency.

Growth Drivers2 items

The Humanes Antithrombin III Konzentrat market is driven by the rising prevalence of hereditary antithrombin deficiency, which is increasing the demand for effective treatments, thereby contributing to the growth forecast.

Advances in recombinant DNA technology are enabling the development of more efficient and cost-effective production methods, which is expected to drive the growth of the Humanes Antithrombin III Konzentrat market size.

Restraints2 items

The high cost of antithrombin III concentrates is a significant restraint on the Humanes Antithrombin III Konzentrat market, as it limits access to these life-saving treatments for many patients, particularly in developing countries.

Stringent regulatory requirements for the approval of antithrombin III concentrates are hindering the entry of new players into the market, which can limit competition and innovation in the Humanes Antithrombin III Konzentrat market.

Opportunities2 items

The increasing use of antithrombin III concentrates in cardiovascular surgery and other applications is creating new opportunities for growth in the Humanes Antithrombin III Konzentrat market.

Emerging markets, such as Asia-Pacific, offer significant opportunities for growth due to their large and growing populations, increasing healthcare spending, and rising demand for antithrombin III concentrates, which is expected to drive the Humanes Antithrombin III Konzentrat market size.

Challenges2 items

The Humanes Antithrombin III Konzentrat market faces challenges related to the supply chain, including the sourcing of high-quality raw materials and the management of inventory levels, which can impact the availability and cost of antithrombin III concentrates.

The market is also subject to macroeconomic factors, such as changes in government policies, reimbursement rates, and economic conditions, which can affect the growth forecast and Humanes Antithrombin III Konzentrat market size.

Market Segmentation

Loading chart…

The Humanes Antithrombin III Konzentrat segmentation by application is a critical aspect of understanding the market dynamics. This market is primarily driven by its use in therapeutic applications, where antithrombin III is used to prevent and treat thrombosis. The application segment can be further divided into subtypes such as treatment of hereditary antithrombin deficiency and prevention of thrombosis in patients undergoing surgical procedures.

Another significant segment in the Humanes Antithrombin III Konzentrat market is based on types, which includes subtypes such as plasma-derived and recombinant antithrombin III. The plasma-derived type is obtained from human plasma and is used to treat patients with hereditary antithrombin deficiency. The recombinant type, on the other hand, is produced through genetic engineering and offers a more consistent and reliable supply. Understanding these types and their applications is crucial for market taxonomy and analyzing the overall market size.

Humanes Antithrombin III Konzentrat Segmentation Breakdown6 items

Application

Clinical Treatment

Scientific Research

Types

Freeze-dried

Liquid

Regional Insights

Loading chart…

The Humanes Antithrombin III Konzentrat market growth is anticipated to vary across regions, with North America emerging as the largest region, accounting for approximately 35% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of antithrombin III concentrates, favorable policies, and significant investments in healthcare infrastructure.

In North America, key drivers include a mature ecosystem, high demographics awareness, and significant infrastructure development. Europe is driven by policies supporting the use of antithrombin III concentrates, a well-established ecosystem, and a high level of adoption. Asia Pacific is fueled by increasing investments in healthcare, growing demographics, and expanding infrastructure. Latin America and Middle East & Africa are driven by improving infrastructure, growing adoption, and increasing investments in healthcare.

The regional forecast indicates that the Humanes Antithrombin III Konzentrat market will experience significant growth, with Asia Pacific expected to drive the market forward. The region's large population, increasing demographics awareness, and growing ecosystem maturity will contribute to its rapid growth. As the market continues to evolve, it is essential to monitor regional trends and market growth to capitalize on emerging opportunities.

Competitive Landscape

The Humanes Antithrombin III Konzentrat market is moderately consolidated, driven by a mix of global players and local/regional companies. The Humanes Antithrombin III Konzentrat competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies emphasize distribution and pricing strategies.

Companies employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies must develop unique value propositions, such as technology, service model, channel strength, customization, or cost advantages. The following companies have adopted distinct strategies:

Octapharma: regional expansion

Baxalta: premium pricing

Grifols: vertical integration

Lee BioSolutions: OEM tie-ups

ATryn: innovation pipeline

LFB: local manufacturing

Key Humanes Antithrombin III Konzentrat Companies11 items

Octapharma

Baxalta

Grifols

Lee BioSolutions

ATryn

LFB

Shire

CSL Limited

Kedrion

Takeda Pharmaceutical

Nihon Pharmaceutical

Market Ecosystem

The Humanes Antithrombin III Konzentrat ecosystem encompasses a complex network of upstream, midstream, and downstream participants. Upstream, technology providers and suppliers deliver crucial components, while midstream integrators and manufacturers produce the final product. Downstream, channels and end users interact to create and capture value. Understanding this ecosystem is essential for conducting a thorough value chain analysis.

Raw material suppliers — provide essential components

OEMs / manufacturers — produce Humanes Antithrombin III Konzentrat

Technology providers — deliver enabling technologies

Distributors / channel partners — facilitate product distribution

End users / buyers — purchase and utilize the product

Regulators/standards bodies — establish and enforce industry standards

Service providers / after-sales — offer support and maintenance services

In the Humanes Antithrombin III Konzentrat ecosystem, control points are primarily held by regulators and end users, who influence adoption through their purchasing decisions and compliance requirements. Dependency risks arise from input constraints, standards, and approvals, which can impact the availability and quality of the final product. Additionally, switching costs and partnerships can create barriers to entry, while interoperability requirements may vary by region, affecting the ecosystem's dynamics and value flow.

Recent Industry Insights

The Humanes Antithrombin III Konzentrat industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between pharmaceutical companies to enhance production capabilities, have been a key focus area. Additionally, there have been notable mergers and acquisitions, with major players expanding their portfolios to include Humanes Antithrombin III Konzentrat products. Furthermore, advancements in technology have led to the launch of new products with improved purity and efficacy.

Regulatory changes, including updated guidelines for the approval of Humanes Antithrombin III Konzentrat products, have also had a profound impact on the industry. A shift in consumer trends towards personalized medicine has driven the demand for more targeted therapies, while enterprise trends have emphasized the need for innovative manufacturing processes. Funding rounds and expansions have enabled companies to invest in research and development, driving Humanes Antithrombin III Konzentrat industry trends forward.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Humanes Antithrombin III Konzentrat market. The market attractiveness is moderate, driven by the growing demand for antithrombin III concentrates in the treatment of hereditary antithrombin deficiency. The competitive intensity is high, with several key players competing for market share. Looking ahead, the long-term Humanes Antithrombin III Konzentrat market outlook is promising, with opportunities for innovation and growth.

The innovation landscape is evolving, with a focus on improving production processes and developing new formulations. However, the demand-supply balance is a key concern, with potential shortages in certain regions. Key risk factors include regulatory changes, supply chain disruptions, and intense competition. Overall, decision-makers must carefully consider these factors to navigate the complex Humanes Antithrombin III Konzentrat market.

11 items

1. Executive Summary

2. Humanes Antithrombin III Konzentrat Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Humanes Antithrombin III Konzentrat Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Humanes Antithrombin III Konzentrat Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Clinical Treatment

6.1.2. Scientific Research

6.2. Global Humanes Antithrombin III Konzentrat Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Freeze-dried

6.2.2. Liquid

6.3. Global Humanes Antithrombin III Konzentrat Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Humanes Antithrombin III Konzentrat Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Humanes Antithrombin III Konzentrat Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Humanes Antithrombin III Konzentrat Market Competition by Key Manufacturers

8.1. Global Humanes Antithrombin III Konzentrat Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Humanes Antithrombin III Konzentrat: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Octapharma

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Baxalta

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Grifols

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Lee BioSolutions

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. ATryn

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. LFB

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Shire

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. CSL Limited

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Kedrion

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Takeda Pharmaceutical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Nihon Pharmaceutical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Humanes Antithrombin III Konzentrat Market

Figure 4: Global Humanes Antithrombin III Konzentrat Market: Drivers

Figure 5: Global Humanes Antithrombin III Konzentrat Market: Challenges

Figure 6: Global Humanes Antithrombin III Konzentrat Market: Trends

Figure 7: Global Humanes Antithrombin III Konzentrat Market: Opportunity

Figure 8: Global Humanes Antithrombin III Konzentrat Market: Restraint

Figure 9: Global Humanes Antithrombin III Konzentrat Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Humanes Antithrombin III Konzentrat Market Value (USD Million) By Region

Figure 15: Global Humanes Antithrombin III Konzentrat Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Humanes Antithrombin III Konzentrat Market Value (USD Million) By Region

Figure 23: Global Humanes Antithrombin III Konzentrat Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Humanes Antithrombin III Konzentrat Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Humanes Antithrombin III Konzentrat Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Humanes Antithrombin III Konzentrat Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Humanes Antithrombin III Konzentrat Market Value (USD Million) By Region

Table 10: Global Humanes Antithrombin III Konzentrat Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Humanes Antithrombin III Konzentrat Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Humanes Antithrombin III Konzentrat Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Humanes Antithrombin III Konzentrat Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Octapharma Basic Information And Sales Area

Table 31: Octapharma. Products Portfolio

Table 32: Baxalta Basic Information And Sales Area

Table 33: Baxalta. Products Portfolio

Table 34: Grifols Basic Information And Sales Area

Table 35: Grifols. Products Portfolio

Table 36: Lee BioSolutions Basic Information And Sales Area

Table 37: Lee BioSolutions. Products Portfolio

Table 38: ATryn Basic Information And Sales Area

Table 39: ATryn. Products Portfolio

Table 40: LFB Basic Information And Sales Area

Table 41: LFB. Products Portfolio

Table 42: Shire Basic Information And Sales Area

Table 43: Shire. Products Portfolio

Table 44: CSL Limited Basic Information And Sales Area

Table 45: CSL Limited. Products Portfolio

Table 46: Kedrion Basic Information And Sales Area

Table 47: Kedrion. Products Portfolio

Table 48: Takeda Pharmaceutical Basic Information And Sales Area

Table 49: Takeda Pharmaceutical. Products Portfolio

Table 50: Nihon Pharmaceutical Basic Information And Sales Area

Table 51: Nihon Pharmaceutical. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Humanes Antithrombin III Konzentrat Market Value (USD Million) By Region

Table 57: Global Humanes Antithrombin III Konzentrat Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Humanes Antithrombin III Konzentrat Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	192.00 million
Revenue forecast in 2033	334.86 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Octapharma; Baxalta; Grifols; Lee BioSolutions; ATryn; LFB; Shire; CSL Limited; Kedrion; Takeda Pharmaceutical; Nihon Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

The increasing use of antithrombin III concentrates in cardiovascular surgery and other applications is creating new opportunities for growth in the Humanes Antithrombin III Konzentrat market.

Challenges2 items

Market Segmentation

Loading chart…

Humanes Antithrombin III Konzentrat Segmentation Breakdown6 items

Application

Clinical Treatment

Scientific Research

Types

Freeze-dried

Liquid

Regional Insights

Loading chart…

Competitive Landscape

Octapharma: regional expansion

Baxalta: premium pricing

Grifols: vertical integration

Lee BioSolutions: OEM tie-ups

ATryn: innovation pipeline

LFB: local manufacturing

Key Humanes Antithrombin III Konzentrat Companies11 items

Octapharma

Baxalta

Grifols

Lee BioSolutions

ATryn

LFB

Shire

CSL Limited

Kedrion

Takeda Pharmaceutical

Nihon Pharmaceutical

Market Ecosystem

Raw material suppliers — provide essential components

OEMs / manufacturers — produce Humanes Antithrombin III Konzentrat

Technology providers — deliver enabling technologies

Distributors / channel partners — facilitate product distribution

End users / buyers — purchase and utilize the product

Regulators/standards bodies — establish and enforce industry standards

Service providers / after-sales — offer support and maintenance services

Recent Industry Insights

Analyst Overview

Table of Contents